Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

NCT02638909 is registered in ClinicalTrials.gov with Criterium, Inc. as lead sponsor.

NCT NCT02638909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02638909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Lead sponsor
Criterium, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2015
Completion date
March 29, 2018
Enrollment
4 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, colorectal adenocarcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, hepatocellular adenocarcinoma, pancreatic adenocarcinoma